Semaglutide is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an add-on to the treatment process that also utiilises diet and exercise.

As part of the deal, Lupin will pay Zydus upfront licensing fees and milestone-based payments linked to predefined targets.